Skip to content

Site logo

Main menu
  • Company
    • Company overview
    • Stories
    • History
    • Environmental, Social & Governance (ESG)
      • ESG overview
      • Philanthropy
      • Merck Medical Outreach Program
      • Impact investing
      • Transparency disclosures
      • ESG resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct & compliance
    • Diversity & inclusion
    • Policies & positions
    • Business development & licensing
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardio-metabolic disorders
    • Pipeline
    • Discovery & development
    • R&D locations
    • Clinical trials
      • Clinical trials overview
      • Find a trial
      • Diversity in clinical trials
  • Products
    • Products list
    • Safety data sheets
    • Product patents
    • Merck authorized distributors
  • Patients
    • Patients overview
    • Patient support programs
    • Patient resources
    • Patient & treatment education
  • Careers
    • Careers
    • Search jobs
    • Our divisions
      • Research & development
      • Manufacturing & supply
      • Human Health
      • Animal Health
      • Global support functions
    • Veterans
    • Student opportunities
    • Compensation & benefits
    • How we hire
    • MSD Careers
    • Events
    • Talent community
  • Investors
    • Investors overview
    • Events & presentations
    • Financial information
      • Financial information overview
      • SEC filings
    • Stock information
    • Investor resources
      • Investor resources overview
      • Organon resources
      • Request for information
  • Media
    • Media overview
    • News releases
    • Company statements
    • Media library & contacts
    • Company fact sheet
two scientists wearing masks

Our COVID-19 efforts

Learn more
Contact us

Worldwide Countries outside of the United States and Canada.

What can we help you find?

Search for:
Environmental, Social & Governance

Merck for Mothers: Helping end maternal mortality

More than a decade of strategic partnerships, private sector innovation and data-driven impact to help create a world where no woman has to die while giving life

September 14, 2022

Share this article

3 women walking with babies in Nigeria

Giving birth can be one of the most beautiful and joyous experiences in a woman’s life, but for many — too many — it can be a scary and tragic event.

According to the World Health Organization, approximately 295,000 women died globally during and following childbirth in 2017. Most of these deaths (94%) occurred in low- and middle-income countries. Most of these deaths could have been prevented.

If we don’t do more, mothers, daughters and granddaughters will continue to lose their lives. And their loss will impact many.

Ken Frazier quote

The birth of Merck for Mothers

In 2011, in response to this crisis, our company created Merck for Mothers, a $500 million global initiative to help create a world where no woman has to die while giving life.

“By helping address one of the oldest and most preventable global health tragedies, we believe Merck for Mothers will have an important impact on society,” said Ken Frazier, Merck’s chairman and then-CEO, as he introduced this new program at the United Nations (UN) General Assembly.

Merck for Mothers began its mission by joining the UN and collaborators around the globe to apply its scientific and business expertise to help save women’s lives, aligned with Sustainable Development Goal 3.1 to reduce the global maternal mortality ratio to less than 70 per 100,000 births by 2030. Achieving this goal would save the lives of approximately 1.4 million women between 2016 and 2030.

A sustainable model to make a difference for generations

Focused on advancing high-quality maternity care, harnessing innovations for maternal health and catalyzing solutions that respond to local needs, Merck for Mothers aims to make a difference for women and their communities now and in the future.

Women around the world die during pregnancy and childbirth for a variety of reasons, including a lack of medical supplies or inadequate health care services to address complications. Other times, it’s due to delays in seeking care or difficulties getting to a medical facility. Sometimes, women can’t afford to pay for health services. And often, women do not have information about or access to contraceptives to help them make their own decisions about whether or not to become pregnant.

Merck for Mothers takes a holistic approach to addressing the many factors that impact maternal health. It collaborates across sectors — working with governments, nongovernmental organizations, patient groups, professional associations, entrepreneurs, UN agencies, research institutions, businesses and even other pharmaceutical companies. The initiative also supports innovations across digital, finance, products and policy, and strives to leverage the private sector for public good. Engaging local stakeholders in designing, implementing and evaluating solutions plays an important role in creating sustainable improvements.

“When we invest in mothers, we help build a better future for all."

Mary-Ann Etiebet

Lead, Merck for Mothers

“We’re constantly looking for ways to further scale this impact and, as importantly, make sure it’s sustainable. We share our findings and the lessons we’re learning across countries, so others can use them,” says Etiebet. “We want to ensure that we not only make a difference for today, but for generations to come.”

Making an impact and the ripple effect

For a decade and counting, Merck for Mothers has worked alongside more than 150+ collaborators in more than 60 global sites to find, test, scale and sustain solutions to reduce maternal mortality.

“Our programs directly reach women and health systems. Since 2011, we have helped more than 18 million women have healthier pregnancies and safer childbirths around the world through programs promoting safe, high quality, respectful care,” says Etiebet.

100M+

people reached through improved access to quality facilities

18M

women with access to programs supporting safe, high quality, respectful care

324,000

providers with improved training

And, research shows that investing in maternal health can have a ripple effect. Better maternal health care is a pathway to a lifetime of benefits, both for a woman’s own health and prosperity as well as that of her children, family, community and nation.

infant icon

Infants 15 times more likely to survive

child icon

Children 10 times more likely to finish school

woman icon

Millions of dollars contributed by women to the economy

“When we invest in maternal health, we ensure that hundreds of thousands of women survive pregnancy and childbirth. When that happens, newborns are more likely to survive, children are more likely to stay in school, women are able to make invaluable contributions to their communities and the workforce, health systems are stronger and nations’ economies grow,” explains Etiebet. “We call this the ‘Mom Effect.'”

And, that’s an important impact on society for generations to come.

Explore our progress over the past 10+ years

Timeline:
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

View by:
Ken Frazier visiting a woman in the hospital

2011

Ken Frazier announces launch of Merck for Mothers 

Merck for Mothers and PATH collaborate to identify game-changing technologies

Spearheaded by top scientists from Merck for Mothers and the global nonprofit, PATH, this unique alliance evaluated promising technologies that address the two leading causes of maternal mortality — post-partum hemorrhage (PPH) and preeclampsia — as well as family planning. This collaboration surfaced the ideas of focusing on a heat-stable uterotonic (carbetocin) to address excessive bleeding during childbirth and optimizing magnesium sulfate administration for pregnant women with preeclampsia – two initiatives that we continue to fund today.

2012

Merck for Mothers joins new global partnership — Saving Mothers, Giving Life

This public-private partnership focuses on helping mothers during labor, delivery and the first 24 hours following birth, when an estimated two-thirds of maternal deaths and almost half of infant deaths occur. With a pledge of more than $200 million, the partnership began with programs in Uganda and Zambia, where maternal mortality rates are disproportionately high.

Pregnant mom in India

2013

Merck for Mothers launches $10 million initiative in India

This initiative to improve access to maternal health services will reach nearly 500,000 pregnant women in Uttar Pradesh, Rajasthan and Jharkhand — all areas with high rates of maternal deaths.

Global health, development and business leaders announce new innovative financing partnership

This partnership leverages private sector funding to speed up delivery and access to life-saving health supplies, such as contraceptives, bed nets, and medicines to those in need. Through Pledge Guarantee for Health (PGH), this new financing mechanism helps increase the impact of each dollar of donor funding and ultimately improve health care access and outcomes for the millions who are helped by foreign aid.

Through the partnership, Merck and other private sector suppliers step up to provide up-front price discounts to aid recipients who utilize PGH to purchase their life-saving health supplies.

woman holding baby smiling

Merck for Mothers launches programs in the U.S.

The maternal mortality rate in the U.S. has nearly doubled since 1990. More than 50,000 women a year — one every 10 minutes — nearly die from severe complications they experience during pregnancy or childbirth. With an initial commitment of $6 million, these programs aim to enhance community care initiatives for high-risk women before, during and after childbirth; implement standard approaches to address obstetric emergencies; and strengthen data collection and reviews to better understand why maternal deaths occur and how to improve practices and patient care.

primary article image

2014

Merck, Ferring Pharmaceuticals and WHO announce collaboration to prevent excessive bleeding in women after childbirth

Merck, Ferring Pharmaceuticals and WHO collaborate to advance a new, proprietary formulation of carbetocin to prevent excessive bleeding in women after childbirth. A primary benefit of carbetocin is its ability to remain stable at room temperature, even in hot and tropical climates, unlike oxytocin, the standard medicine administered for the prevention of PPH. Oxytocin is temperature-sensitive and requires sustained cold distribution and storage, which is difficult to achieve in many of these areas of high maternal mortality.

primary article image

2015

Merck for Mothers explores digital technologies to mobilize maternal health 

Merck for Mothers commits resources to invent or enhance existing solutions to tackle some of the most critical obstacles standing in the way of delivering quality maternity care and contraceptive services in low- and middle-income countries. This commitment leads to a new wave of smart, innovative apps and digital platforms – like the Safe Delivery App, mDoc, Project iDeliver, AskNivi, MomCare, Together for Her Health, among others.

Merck and Merck for Mothers help advance a new set of UN global goals

The Sustainable Development Goals (SDGs) are formally adopted at the 70th UNGA. They represent the international community’s aspirations for improving the lives of the world’s poorest people by 2030.

Merck for Mothers has now reached 5 million women worldwide through its programs

teal bag that contains supplies for expectant mothers

2016

Employees across the globe join the fight to end maternal mortality

Employee volunteers participate in activities such as assembling post-natal kits for soon-to-be mothers in Uganda as a means of encouraging them to seek care to support healthy pregnancies and deliveries. The kits include essential supplies to aid the health and safety of a mother and newborn after birth. This activity, among others, become annual events where employees can help amplify our impact. 

Merck for Mothers’ collaborators complete their first maternity waiting home in Zambia

Maternity waiting homes — residences located near health facilities where pregnant women can stay before they go into labor — can make all the difference for pregnant women in rural Zambia, where the distance between home and a health facility can be a matter of life and death.

men working on a building
primary article image

2017

Merck for Mothers teams up with stakeholders across India to launch Manyata

Merck for Mothers, Jhpiego India and the Federation of Obstetric and Gynecological Societies of India partnered to launch Manyata – an ambitious agenda to improve quality of maternity and newborn care services in private facilities by training doctors, nursing and administrative staff on essential clinical, facility and patient care protocols in India.

nurse helping with paperwork

Merck for Mothers commits $10 million and business expertise to the Global Financing Facility

In support of the UN Secretary-General’s Every Woman Every Child strategy to improve maternal and child health in low- and lower-middle-income countries, the goal is to prevent an estimated 3.8 million maternal deaths, 101 million child deaths and 21 million stillbirths by 2030. Merck is the first private sector investor and helped bring other private sector investors to the table.

Training health care workers in India

Merck for Mothers launches the world’s first maternal and newborn health development bond with public and private sector collaborators

The Utkrisht Development Impact Bond leverages private investor capital to incentivize private maternity providers in Rajasthan, India to improve the quality of care they deliver. Interventions will reach up to 600,000 pregnant women with improved care during delivery and could lead up to 10,000 lives being saved over a five-year period. 

pregnant woman being examined in the hospital

2018

Ferring Pharmaceuticals and Merck announce completion of carbetocin clinical trial, the largest clinical trial ever conducted in postpartum hemorrhage

The trial of heat-stable carbetocin showed it to be as safe and effective as oxytocin in preventing postpartum hemorrhage, the largest direct cause of maternal death. The trial included nearly 30,000 women from 10 countries.

“This has the potential to change the paradigm in how we save more mothers from dying during childbirth,” said Dr. Julie L. Gerberding, Merck’s chief patient officer.

two pregnant women

Merck announces new U.S. initiative — Safer Childbirth Cities

Through this initiative, Merck for Mothers will provide grants to help cities with poor maternal health outcomes develop and implement creative, multi-sector solutions to save women’s lives, improve maternal health and narrow racial disparities.

Merck for Mothers publishes first research compendium to advance collective understanding of maternal mortality

The research compendium, Evidence for Impact, collates actionable and real-time evidence about what works and what doesn’t to expand knowledge that will help encourage greater investment in women’s health. Merck for Mothers publishes a second compendium in 2020.
Mother with her baby and toddler in Romania

2019

Merck for Mothers has now reached 10 million women worldwide through its programs

African family with baby

The MOMs (Maternal Outcomes Matters) Initiative launched

A partnership between Merck for Mothers, the U.S. International Development Finance Corporation, Credit Suisse and USAID to stimulate, advance and scale innovations that contribute to a healthy pregnancy and safe childbirth. It will invest $50M in local businesses that are working to improve maternal health in regions of the world where high rates of women are dying from pregnancy and childbirth. (Photo credit: LifeBank)

Pregnant belly and "Hear Her" CDC campaign logo

2020

Merck for Mothers provides funding to help support the CDC’s new maternal health communication campaign, Hear Her

Hear Her brings attention to maternal mortality and provides support to pregnant and postpartum women to speak up when something doesn’t feel right.

Merck commits $3M to address maternal health needs during COVID-19 pandemic

2021

Merck announces fifth round of global grants to tackle maternal mortality and promote health equity worldwide

Merck for Mothers supports the corporate grant program which enables Merck offices around the world to aid nongovernmental organizations that are improving maternal health. The program responds to local women’s needs, focusing on how resources can increase health equity in maternity care and support.

Merck announces additional $150M investment through 2025 to help end maternal mortality inequities, building on the $500M commitment made in 2011

This investment comes at a pivotal time for the global health community as the COVID-19 pandemic continues to stretch health systems, disrupting networks of care that support healthy pregnancies and safe childbirth.

mother and daughter in the hospital

2022

Merck for Mothers has now reached more than 18 million women worldwide through its programs.

Merck for Mothers celebrates 10 years and counting

Featured banner image

Strategic partnerships, private sector innovation and data-driven impact

Our work continues in order to help create a world where no woman has to die while giving life

Learn more about Merck for Mothers
Discover more stories

Safeguarding the environment through green chemistry

One scientist’s commitment to dengue fever research

Collaborating to help make cancer care more accessible worldwide

View all stories

 

Explore more in

Collaboration
Corporate responsibility
Merck for Mothers
Our people

Related links

related content image #1

Our culture and values

It all comes back to saving and improving lives

related content image #2

Environmental, Social & Governance (ESG)

Supporting society, people and communities around the world is fundamental to our long-term success

related content image #3

Careers

Are you passionate about building a meaningful career? Come invent with us!

Connect with us on social

social icon social icon social icon social icon social icon
  • MerckHelps
    Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients
  • Merck Access Program
    Information about insurance coverage and financial assistance options for eligible patients
  • Clinical trials
    Learn about our clinical trials and find available studies
  • Merck Manuals
    Medical information source covering thousands of topics in all fields of medicine
  • Environmental, Social & Governance (ESG) Report
    Reporting on our commitment to operating responsibly to benefit society
  • Merck for Mothers
    An initiative to create a world where no woman has to die giving life
  • Merck Animal Health
    The global animal health business unit of Merck
  • Health Plan - Transparency in Coverage
    In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Transparency disclosure
  • Terms of use
  • Accessibility
  • Sitemap
Copyright © 2023 Merck & Co., Inc., Rahway, NJ USA, and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.
Accessibility icon View Privacy Shield Verification Status View APEC CBPR Privacy Certification Status

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

You are leaving Merck.com

Continue

Welcome to Merck.com

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.

Continue